These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27397723)

  • 21. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
    Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
    Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.
    Beca F; Lee SSK; Pareja F; Da Cruz Paula A; Selenica P; Ferrando L; Gularte-Mérida R; Wen HY; Zhang H; Guerini-Rocco E; Rakha EA; Weigelt B; Reis-Filho JS
    Histopathology; 2019 Dec; 75(6):931-937. PubMed ID: 31361912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
    Balko JM; Giltnane JM; Wang K; Schwarz LJ; Young CD; Cook RS; Owens P; Sanders ME; Kuba MG; Sánchez V; Kurupi R; Moore PD; Pinto JA; Doimi FD; Gómez H; Horiuchi D; Goga A; Lehmann BD; Bauer JA; Pietenpol JA; Ross JS; Palmer GA; Yelensky R; Cronin M; Miller VA; Stephens PJ; Arteaga CL
    Cancer Discov; 2014 Feb; 4(2):232-45. PubMed ID: 24356096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
    Weisman PS; Ng CK; Brogi E; Eisenberg RE; Won HH; Piscuoglio S; De Filippo MR; Ioris R; Akram M; Norton L; Weigelt B; Berger MF; Reis-Filho JS; Wen HY
    Mod Pathol; 2016 May; 29(5):476-88. PubMed ID: 26939876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-Negative Breast Cancer: Next-Generation Sequencing for Target Identification.
    Marotti JD; de Abreu FB; Wells WA; Tsongalis GJ
    Am J Pathol; 2017 Oct; 187(10):2133-2138. PubMed ID: 28734944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
    Munzone E; Gray KP; Fumagalli C; Guerini-Rocco E; Láng I; Ruhstaller T; Gianni L; Kammler R; Viale G; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Barberis M; Colleoni M
    Breast Cancer Res Treat; 2018 Jul; 170(2):351-360. PubMed ID: 29589138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
    Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
    Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are acinic cell carcinomas of the breast and salivary glands distinct diseases?
    Piscuoglio S; Hodi Z; Katabi N; Guerini-Rocco E; Macedo GS; Ng CK; Edelweiss M; De Mattos-Arruda L; Wen HY; Rakha EA; Ellis IO; Rubin BP; Weigelt B; Reis-Filho JS
    Histopathology; 2015 Oct; 67(4):529-37. PubMed ID: 25688711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
    BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
    PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
    Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
    Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
    Santarpia L; Bottai G; Kelly CM; Győrffy B; Székely B; Pusztai L
    Oncologist; 2016 Sep; 21(9):1063-78. PubMed ID: 27384237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
    Wong-Brown MW; Meldrum CJ; Carpenter JE; Clarke CL; Narod SA; Jakubowska A; Rudnicka H; Lubinski J; Scott RJ
    Breast Cancer Res Treat; 2015 Feb; 150(1):71-80. PubMed ID: 25682074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.
    Liu H; Murphy CJ; Karreth FA; Emdal KB; White FM; Elemento O; Toker A; Wulf GM; Cantley LC
    Cancer Discov; 2018 Mar; 8(3):354-369. PubMed ID: 29203461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
    Au CH; Wa A; Ho DN; Chan TL; Ma ES
    Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
    Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    Podo F; Santoro F; Di Leo G; Manoukian S; de Giacomi C; Corcione S; Cortesi L; Carbonaro LA; Trimboli RM; Cilotti A; Preda L; Bonanni B; Pensabene M; Martincich L; Savarese A; Contegiacomo A; Sardanelli F
    Clin Cancer Res; 2016 Feb; 22(4):895-904. PubMed ID: 26503945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
    Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.